Your browser doesn't support javascript.
loading
Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
Ker, Khor Jia; Teske, Noelle M; Feng, Rui; Chong, Benjamin F; Werth, Victoria P.
Afiliação
  • Ker KJ; National Skin Centre, Singapore, Singapore; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Teske NM; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Feng R; Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Chong BF; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: ben.chong@utsouthwestern.edu.
  • Werth VP; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; Medical Research, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania. Electronic address: werth@mail.med.upenn.edu.
J Am Acad Dermatol ; 79(6): 1053-1060.e3, 2018 Dec.
Article em En | MEDLINE | ID: mdl-29969701
ABSTRACT

BACKGROUND:

Long-term studies characterizing disease course of cutaneous lupus erythematosus (CLE) patients on standard-of-care treatments are lacking.

OBJECTIVE:

We characterized and compared disease course of CLE patients using Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).

METHODS:

In total, 83 CLE patients with CLASI scores collected from ≥3 study visits within 2 years had disease activity and damage trends calculated by average change scores (ACS). Trends were classified as improved (ACS ≤-3), worsened (ACS ≥3), or stable (-3 < ACS < 3). Linear regression models compared CLASI trends between groups.

RESULTS:

Most patients (72.73%) with initial CLASI activity (CLASI-A) scores >9 (N = 33) had improved disease activity versus 14.00% of those with initial CLASI-A scores ≤9 (N = 50). Linear regression analyses showed significant improvement in CLASI-A scores in patients of minority races (P < .05), with baseline CLASI-A scores >9 (P < .0001), baseline CLASI damage (CLASI-D) scores ≥10 (P = .0001), and CLE disease duration ≤1 year (P = .01). Of 28 patients with baseline CLASI-D scores ≥10, 35.71% had improvements in damage, while 5.26% of patients with initial CLASI-D scores of 5-9 (N = 19) and 0% with initial CLASI-D scores <5 (N = 36) (P = .0005) had improvements.

LIMITATIONS:

Limitations include small sample size.

CONCLUSION:

Baseline CLASI-A score >9, minority race, and short disease duration predict CLE disease activity improvement. A baseline CLASI-D score ≥10 is associated with disease damage improvement.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Cutâneo Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Cutâneo Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article